Ente Ospedaliero Ospedali Galliera Di Genova — Clinical Trial Site

28 Registered trials

8 Currently recruiting

Organisation

Ente Ospedaliero Ospedali Galliera Di Genova

Location

Genoa, Italy

Identifier

ORG-100007267

Address

Mura Delle Cappuccine 14, 16128, Italy

Departments

Centro della Microcitemia e delle Anemie Congenitive
Dipartimento area di medicina, S.C. Oncologia medica
Microcitemia and congenital anemia and Iron, dismetabolism centre
Microcitemia, anemie congenite e dismetabolismo del ferro
N/A
Nuclear Medicine
Oncologia medica
Oncology
Reparto di Malattie Infettive
S.C. Laboratorio di analisi
S.C. Medicina Nucleare
S.C. Oncologia
S.C. Oncologia Medica
S.S.D. Centro della Microcitemia e Anemie Congenite
S.S.D. Microcitemia Anemie Congenite e Dismetabolismo del ferro
S.S.D. Microcitemia e delle Anemie Congenite
S.S.D. Microcitemia, Anemie Congenite e Dismetabolismo del Ferro
SC Oncologia Medica
Struttura Complessa Oncologia Medica
Unità di livello 1, 2 e 3

Clinical trials at this site (28)

Search interface

Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Not authorised

2024-512754-16-00 Prostate cancer 5
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload … Pending

2023-508604-37-00 Non-transfusion dependent beta-thalassemia (NTDT), Beta 4
Clinical study to check the Efficacy and Safety of Mitapivat in Patients with Sickle Cell Disease Pending

2024-515202-84-00 Anemia in subjects with sickle cell disease (SCD) 10
Use of Sulodexide (VESSEL®) for the prevention of a new episode in elderly patients who have had a first episode of deep vein thrombosis and… Pending

2024-517796-21-00 Prevention of recurrence after a first episode of Venou 5
Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, win… Pending

2024-518402-40-00 Luminal (ER+ve and/or PgR+ve >=1%) invasive breast canc 4
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending

2024-519087-41-00 Breast cancer is the most common form of cancer among w 5
64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending

2025-520861-29-00 Prostate cancer at risk of developing metastatic lesion 5
Use of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to … Pending

2025-520868-17-00 Cancer on the prostatic bed 5
The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting

2024-518645-17-00 Blood and lymphatic diseases 5 2025-10-07
Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Recruiting

2024-516874-31-00 Patients with a low-grade serous epithelial carcinoma o 5 2024-12-10
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02
Randomized double blind phase 2 trial of baby exemestane versus baby tamoxifen in postmenopausal women at high risk for breast cancer Recruiting

2024-520004-26-00 Breast cancer 4 2025-10-01
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi… Recruiting

2023-507396-21-00 transfusion-dependent α- or β-thalassemia or low-risk m 4 2023-03-16
Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (α)-thalassemia Recruiting

2022-502328-35-00 Alpha (α)-thalassemia 4 2023-01-30
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima… Recruiting

2024-515681-14-00 Stage II (pT4)/III colorectal cancer with positive circ 4 2022-05-02
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended

2024-512747-23-00 Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2024-07-30
INSPIRE (INcreased Sun exposure without Pain In Research subjects with EPP). Ended

2023-506735-15-00 Erythropoietic Protoporphyria or X-Linked Protoporphyri 5 2024-04-05
Open-Label and Long-term Extension Study with Dersimelagon (MT-7117) in Subjects with EPP or XLP Ended

2024-514466-38-00 Erythropoietic Protoporphyria (EPP) or X-Linked Protopo 5 2022-04-19
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended

2024-512745-16-00 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2022-04-13
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03
Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended

2023-505830-89-00 metastatic castrate resistant prostate cancer (mCRPC) 6 2020-08-05
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L… Ended

2022-502498-40-00 myelodysplastic syndrome (MDS); beta (β)-thalassemia (T 5 2019-07-26
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27